Efficacy of immune checkpoint inhibitors according to programmed cell death‐ligand 1 expression in patients with non‐small cell lung cancer and brain metastasis: A real‐world prospective observational study
Our study indicated that the outcomes of patients with or without BM treated with ICI were not significantly different. The efficacy of ICI in patients with PD-L1 expression ≥50% would be lower in patients with BM than in those without.
Authors
- Noboru Hattori (ORCID: https://orcid.org/0000-0002-8234-942X)
- Kakuhiro Yamaguchi (ORCID: https://orcid.org/0000-0002-9117-1934)
- Nobuhiro Kanaji (ORCID: https://orcid.org/0000-0001-7365-4927)
- Masaaki Yanai
- Takuya Inoue (ORCID: https://orcid.org/0000-0002-0365-3934)
- Mika Horie (ORCID: https://orcid.org/0009-0008-6385-7278)
- Katsuyuki Hotta (ORCID: https://orcid.org/0000-0002-0112-0843)
- Tetsuya Kubota (ORCID: https://orcid.org/0000-0002-5223-0196)
- Katsuyuki Kiura (ORCID: https://orcid.org/0000-0002-9172-9379)
- Takeshi Masuda (ORCID: https://orcid.org/0000-0003-3557-0049)
- Shoichi Kuyama (ORCID: https://orcid.org/0000-0002-6079-3511)
- Masahiro Yamasaki (ORCID: https://orcid.org/0000-0002-5296-4974)
- Masahiro Kodani
- Kazuya Nishii (ORCID: https://orcid.org/0000-0002-1591-1937)
- Nobuhisa Ishikawa (ORCID: https://orcid.org/0000-0002-0208-2180)
- Nagio Takigawa
- K. Hata
- Ken Masuda (ORCID: https://orcid.org/0000-0002-7736-3737)
- Naoko Matsumoto
- Yukari Tsubata
Institutions
- Shimane University (JP)
- Kawasaki Medical School (JP)
- Kagawa University (JP)
- Okayama University Hospital (JP)
- Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital (JP)
- Hiroshima Prefectural Hospital (JP)
- Hiroshima University Hospital (JP)
- Iwakuni Medical Center (JP)
- Tottori University (JP)
- Kōchi University (JP)
Publication Details
- Journal
- Thoracic Cancer
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1111/1759-7714.15469
- Citations
- 4
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.13
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Nipro
- Daiichi-Sankyo
- Eisai
- Shionogi
- Novartis Pharma
- Chugai Pharmaceutical
- Daiichi Sankyo Europe